P&G Health Q1 FY27 Results: Revenue Rs 363 Cr, PAT Rs 96 Cr and Key Highlights
- August 7, 2026
- Posted by: Kunal Singla
- Category: News
P&G Health Q1 FY27 results declared Aug 6, 2026. Revenue Rs 363 Cr (First Q YoY). PAT Rs 96 Cr (First Q YoY). CMP Rs 6068.0 (-6.13%).
P&G Health Q1 FY27 results were announced on August 6, 2026, on a Standalone basis. P&G Health Q1 FY27 results mark the company’s first reported quarter with revenue at Rs 363 Cr. No prior year comparable data is available. The broader Nifty FMCG index also reflected mixed sentiment during the quarter.
Operating profit for the quarter stood at Rs 99 Cr. Comparable prior year data was not available for this segment. Net profit (PAT) for P&G Health Q1 FY27 results stood at Rs 96.00 Cr. No comparable prior year PAT data is available. The quarterly numbers offer a detailed picture of how the company is navigating the current fmcg environment.
Click Here – Get Free Investment Predictions
P&G Health Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| P&G Health Revenue | 363 | N/A | N/A (First Q) |
| Operating Profit | 99 | N/A | N/A (First Q) |
| Net Profit (PAT) | 96 | N/A | N/A (First Q) |
| Reporting Basis | Standalone | ||
P&G Health Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
P&G Health Q1 FY27 results reflect maiden fundamentals across key financial parameters. Revenue momentum faced near-term headwinds with the top line reaching Rs 363 Cr for the April to June 2026 quarter.
Operating profit stood at Rs 99 Cr, contracting YoY. Management is implementing cost reduction measures to restore operating leverage.
PAT of Rs 96 Cr marks a first-quarter year-on-year improvement. Investors monitoring P&G Health Q1 FY27 results will note this as a key milestone for FY27 tracking.
Key Business Factors in P&G Health Q1 FY27 Results
Revenue Normalisation After Prior Year Headwinds
P&G Health Q1 FY27 results reflect near-term revenue moderation as first-quarter data, attributed to market-specific factors including demand normalisation and channel inventory adjustments.
Operating Profit Under Pressure from Cost Headwinds
Operating profit in P&G Health Q1 FY27 results came in at Rs 99 Cr , weighed down by input cost inflation, employee expenses, and competitive pricing dynamics.
PAT Performance and Profitability Trend
Net profit in P&G Health Q1 FY27 results stood at Rs 96 Cr (no prior year comparable). Near-term profitability moderation is being managed through cost optimisation initiatives.
Dividend Details
No dividend was announced along with P&G Health Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.
FY27 Outlook for P&G Health
P&G Health is positioned to maintain growth momentum into Q2 FY27 and beyond, supported by order visibility, operational improvements, and sector tailwinds. Management guidance points toward continued expansion in the FMCG business with a focus on margin improvement and market share consolidation. Investors tracking P&G Health Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.
P&G Health Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track P&G Health live price and get daily stock recommendations.
P&G Health shares were trading lower at Rs 6068.0 (-6.13%) on August 6, 2026, following the declaration of P&G Health Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 6068.0 on the results date, with a 52-week range reflecting the broader market sentiment toward the fmcg sector.
Key Risks for P&G Health
Sector-Specific Headwinds
Input cost inflation and rural demand slowdown pose risks to margin recovery.
Valuation and Earnings Risk
Valuation risk remains if earnings growth fails to sustain at current levels over the next two to three quarters.
Operational and Financial Risk
Working capital intensity and cash conversion cycle elongation pose risks to standalone cash flows.
Conclusion
P&G Health Q1 FY27 results demonstrate maiden financial performance with revenue at Rs 363 Cr and PAT at Rs 96 Cr on a Standalone basis. Operating leverage and disciplined cost management will be key drivers for the rest of FY27. Investors should track upcoming management commentary on growth drivers and sector developments before taking positions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on P&G Health Q1 FY27 Results
When were P&G Health Q1 FY27 results declared?
Ans. P&G Health Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Standalone basis.
What was P&G Health revenue in Q1 FY27?
Ans. P&G Health Q1 FY27 results show revenue of Rs 363 Cr, First Q compared to Rs N/A Cr in Q1 FY26.
What was P&G Health PAT in Q1 FY27?
Ans. Net profit (PAT) in P&G Health Q1 FY27 results was Rs 96 Cr, First Q year-on-year.
Did P&G Health declare a dividend in Q1 FY27?
Ans. No dividend was declared alongside P&G Health Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.
What is the FY27 outlook for P&G Health?
Ans. P&G Health management has outlined a focus on revenue scaling and margin improvement for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.
How did the P&G Health stock react to Q1 FY27 results?
Ans. P&G Health shares were trading lower at Rs 6068.0 (-6.13%) on August 6, 2026, following the P&G Health Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.
